The international study led by a Virginia Commonwealth University researcher found the medication semaglutide, commonly known ...

Using semaglutide injections, scientists were able to reverse life-threatening cases of liver disease in a new clinical trial published in The New England Journal of Medicine.

A global trial finds Wegovy and Ozempic significantly improve liver health in patients and treats those with advanced fatty ...

The active ingredient in the popular weight loss drug Wegovy may help treat a type of fatty liver disease, according to a new ...

A decision is expected in the fourth quarter of 2025.

Novo Nordisk (NVO) stock in focus as oral Wegovy is accepted for FDA review for chronic weight management. Read more here.

Health Canada begins a priority review of semaglutide 2.4 mg, a weekly treatment by Novo Nordisk for MASH, a liver disease ...

Semaglutide - the active ingredient in medications like Ozempic and WeGovy - is only FDA approved for Type-2 diabetes, but ...

CVS Caremark has selected Novo Nordisk’s Wegovy as the preferred GLP-1 medication for its largest commercial template formularies, effective July 1. In March, Novo Nordisk launched NovoCare Pharmacy ...